199 related articles for article (PubMed ID: 21801593)
1. Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes.
Li W; Sachidanandam K; Ergul A
Neurol Res; 2011 Mar; 33(2):185-91. PubMed ID: 21801593
[TBL] [Abstract][Full Text] [Related]
2. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes.
Harris AK; Elgebaly MM; Li W; Sachidanandam K; Ergul A
Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1213-9. PubMed ID: 18287215
[TBL] [Abstract][Full Text] [Related]
3. Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.
Abdelsaid M; Ma H; Coucha M; Ergul A
Life Sci; 2014 Nov; 118(2):263-7. PubMed ID: 24434796
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes.
Sachidanandam K; Elgebaly MM; Harris AK; Hutchinson JR; Mezzetti EM; Portik-Dobos V; Ergul A
Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2743-9. PubMed ID: 18424628
[TBL] [Abstract][Full Text] [Related]
5. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors.
Kelly-Cobbs AI; Harris AK; Elgebaly MM; Li W; Sachidanandam K; Portik-Dobos V; Johnson M; Ergul A
J Pharmacol Exp Ther; 2011 Apr; 337(1):9-15. PubMed ID: 21205912
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist.
Sudoh K; Yuyama H; Noguchi Y; Fujimori A; Ukai M; Ohtake A; Sato S; Sasamata M; Miyata K
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S390-3. PubMed ID: 15838329
[TBL] [Abstract][Full Text] [Related]
7. The effect of endothelin receptor A antagonism on basilar artery endothelium-dependent relaxation after ischemic stroke.
Coucha M; Li W; Ergul A
Life Sci; 2012 Oct; 91(13-14):676-80. PubMed ID: 22365958
[TBL] [Abstract][Full Text] [Related]
8. Chronic endothelin antagonism restores cerebrovascular function in diabetes.
Dumont AS; Dumont RJ; McNeill JH; Kassell NF; Sutherland GR; Verma S
Neurosurgery; 2003 Mar; 52(3):653-60; discussion 659-60. PubMed ID: 12590691
[TBL] [Abstract][Full Text] [Related]
9. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes.
Sachidanandam K; Portik-Dobos V; Harris AK; Hutchinson JR; Muller E; Johnson MH; Ergul A
Diabetes; 2007 Nov; 56(11):2753-8. PubMed ID: 17670915
[TBL] [Abstract][Full Text] [Related]
10. Effects of selective and non-selective endothelin receptor blockade on ET-1-induced pressor response in the hamster.
Honoré JC; Fecteau MH; Wessale JL; D'Orléans-Juste P
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S68-71. PubMed ID: 15838362
[TBL] [Abstract][Full Text] [Related]
11. End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade.
Vernerová Z; Kujal P; Kramer HJ; Bäcker A; Cervenka L; Vaneckova I
Physiol Res; 2009; 58 Suppl 2():S69-S78. PubMed ID: 20131938
[TBL] [Abstract][Full Text] [Related]
12. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Lee TM; Chen CC; Lin MS; Chang NC
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1871-9. PubMed ID: 18281380
[TBL] [Abstract][Full Text] [Related]
13. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
[TBL] [Abstract][Full Text] [Related]
14. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
Saleh MA; Pollock JS; Pollock DM
J Pharmacol Exp Ther; 2011 Jul; 338(1):263-70. PubMed ID: 21471190
[TBL] [Abstract][Full Text] [Related]
15. Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.
Abdelsaid M; Kaczmarek J; Coucha M; Ergul A
Life Sci; 2014 Nov; 118(2):268-73. PubMed ID: 24447630
[TBL] [Abstract][Full Text] [Related]
16. Effects of endothelin receptor blockade on hypervasoreactivity in streptozotocin-diabetic rats: vessel-specific involvement of thromboxane A2.
Arikawa E; Cheung C; Sekirov I; Battell ML; Yuen VG; McNeill JH
Can J Physiol Pharmacol; 2006; 84(8-9):823-33. PubMed ID: 17111027
[TBL] [Abstract][Full Text] [Related]
17. Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.
Chichorro JG; Zampronio AR; Souza GE; Rae GA
Pain; 2006 Jul; 123(1-2):64-74. PubMed ID: 16563629
[TBL] [Abstract][Full Text] [Related]
18. Alteration in endothelin receptor sub-type responsiveness and in the endothelin-TXA(2) mimetic U46619 interaction, in type-2 hypertensive diabetic Zucker rats.
Ajayi AA; Ogungbade GO; Hercule HC; Oyekan AO; Mutembei L
Diabetes Res Clin Pract; 2004 Mar; 63(3):155-69. PubMed ID: 14757287
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes.
Elgebaly MM; Portik-Dobos V; Sachidanandam K; Rychly D; Malcom D; Johnson MH; Ergul A
Vascul Pharmacol; 2007; 47(2-3):125-30. PubMed ID: 17597010
[TBL] [Abstract][Full Text] [Related]
20. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.
Opocenský M; Kramer HJ; Bäcker A; Vernerová Z; Eis V; Cervenka L; Certíková Chábová V; Tesar V; Vanecková I
Hypertension; 2006 Nov; 48(5):965-71. PubMed ID: 17015777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
